4//SEC Filing
Rosenberg Noah L. 4
Accession 0001209191-20-051614
CIK 0001438533other
Filed
Sep 21, 8:00 PM ET
Accepted
Sep 22, 9:20 PM ET
Size
7.0 KB
Accession
0001209191-20-051614
Insider Transaction Report
Form 4
Retrophin, Inc.RTRX
Rosenberg Noah L.
Chief Medical Officer
Transactions
- Sale
Common Stock
2020-09-22$18.59/sh−750$13,943→ 28,305 total - Award
Common Stock
2020-09-18+3,000→ 29,055 total
Footnotes (2)
- [F1]On May 9, 2019, the reporting person was granted performance restricted stock units (PRSUs) covering 6,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 18, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the first 280 patients in the sparsentan PROTECT Phase 3 Study had been enrolled.
- [F2]The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.
Documents
Issuer
Retrophin, Inc.
CIK 0001438533
Entity typeother
Related Parties
1- filerCIK 0001579649
Filing Metadata
- Form type
- 4
- Filed
- Sep 21, 8:00 PM ET
- Accepted
- Sep 22, 9:20 PM ET
- Size
- 7.0 KB